Skip to main content
SpringerLink
Log in

Prognostic Factors

  • Chapter
  • First Online:
Hodgkin Lymphoma

Part of the book series: Hematologic Malignancies ((HEMATOLOGIC))

Abstract

The concept that Hodgkin lymphoma (initially called Hodgkin’s disease) passes through successive clinical stages with increasing spread of the disease and progressive worsening of prognosis was developed early on [1]. Different staging classifications were proposed based on the anatomic extent of disease [2–8]. A consensus was reached at the Workshop on the Staging of Hodgkin’s Disease at Ann Arbor in 1971 [9], and the Ann Arbor staging classification was universally adopted. It remains the basis for the evaluation of patients with Hodgkin lymphoma, and its prognostic significance has been documented in numerous studies of patients treated with different treatment modalities [10–17]. Survival curves according to the Ann Arbor stages for more than 14,000 patients in the International Database on Hodgkin’s Disease are shown in Fig. 7.1 [14]

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 199.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

ABVD:

Adriamycin, bleomycin, vinblastine, dacarbazine

BEACOPPesc:

Bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisolone, escalated

BNLI:

British National Lymphoma Investigation

CALGB:

Cancer and Leukemia Group B

ECOG:

Eastern Cooperative Oncology Group

EORTC:

European Organisation for Research and Treatment of Cancer

ESR:

Erythrocyte sedimentation rate

FDG:

2-[18F]fluoro-2-deoxy-d-glucose

GELA:

Groupe d’Etudes des Lymphomes de l’Adulte

GHSG:

German Hodgkin Study Group

IPS:

International Prognostic Score

LDH:

Lactic dehydrogenase

MOPP:

Mechlorethamine, vincristine, procarbazine, prednisolone

NCI-C:

National Cancer Institute of Canada

NCI-US:

National Cancer Institute of the United States

PET:

Positron emission tomography

SWOG:

Southwest Oncology Group

References

  1. Reed DM. On the pathological changes in Hodgkin’s disease, with especial reference to its relation to tuberculosis. Johns Hopkins Hosp Rep. 1902;10:133–96.

    Google Scholar 

  2. Banfi A, Bonadonna G, Buraggi G, et al. Proposta di classificazione e terapia della malattia di Hodgkin. Tumori. 1965;51:97–112.

    PubMed  CAS  Google Scholar 

  3. Easson EC, Russell MH. The cure of Hodgkin’s disease. BMJ. 1963;1963:1704–7.

    Article  Google Scholar 

  4. Jelliffe AM, Thomson AD. The prognosis in Hodgkin’s disease. Br J Cancer. 1955;9:21–36.

    Article  PubMed  CAS  Google Scholar 

  5. Kaplan HS. On the natural history, treatment and prognosis of Hodgkin’s disease. In: Harvey lectures 1968–1969. New York: Academic; 1970.

    Google Scholar 

  6. Musshoff K, Stamm H, Lummel G, et al. Zur prognose der lymphogranulomatose. Klinisches bild un strahlentherapie. Freiburger Krankengut 1938-1958. In: Keiderling W, editor. Beiträge zur Inneren Medizin. Stuttgart: FK Schattauer; 1964.

    Google Scholar 

  7. Peters MV. A study of survivals in Hodgkin’s disease treated radiologically. Am J Roentgenol. 1950;63:299–311.

    Google Scholar 

  8. Rosenberg SA. Report of the Committee on the Staging of Hodgkin’s Disease. Cancer Res. 1966;26:1310.

    Google Scholar 

  9. Carbone PP, Kaplan HS, Musshoff K, et al. Report of the Committee on Hodgkin’s disease staging classification. Cancer Res. 1971;31:1860–1.

    PubMed  CAS  Google Scholar 

  10. Aisenberg AC, Qazi R. Improved survival in Hodgkin’s disease. Cancer. 1976;37:2423–9.

    Article  PubMed  CAS  Google Scholar 

  11. Davis S, Dahlberg S, Myers MH, et al. Hodgkin’s disease in the United States: a comparison of patient characteristics and survival in the Centralized Cancer Patient Data System and the Surveillance, Epidemiology, and End Results Program. J Natl Cancer Inst. 1987;78:471–8.

    PubMed  CAS  Google Scholar 

  12. Gobbi PG, Cavalli C, Federico M, et al. Hodgkin’s disease prognosis: a directly predictive equation. Lancet. 1988;1:675–9.

    Article  PubMed  CAS  Google Scholar 

  13. Hancock BW, Aitken M, Martin JF, et al. Hodgkin’s disease in Sheffield (1971–76) (with computer analysis of variables). Clin Oncol. 1979;5:283–97.

    PubMed  CAS  Google Scholar 

  14. Henry-Amar M, Aeppli DM, Anderson J, et al. Workshop statistical report. In: Somers R, Henry-Amar M, Meerwaldt JH, et al., editors. Treatment strategy in Hodgkin’s disease. INSERM/John Libbey Eurotext: London; 1990.

    Google Scholar 

  15. Kaplan HS. Survival and relapse rates in Hodgkin’s disease: Stanford experience, 1961-71. Monogr Natl Cancer Inst. 1973;36:487–96.

    CAS  Google Scholar 

  16. Musshoff K, Hartmann C, Niklaus B, et al. Results of therapy in Hodgkin’s disease: Freiburg i. Br. 1964-1971. In: Musshoff K, editor. Diagnosis and therapy of malignant lymphoma. Berlin: Springer; 1974.

    Chapter  Google Scholar 

  17. Sutcliffe SB, Gospodarowicz MK, Bergsagel DE, et al. Prognostic groups for management of localized Hodgkin’s disease. J Clin Oncol. 1985;3:393–401.

    PubMed  CAS  Google Scholar 

  18. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol. 1989;7:1630–6.

    PubMed  CAS  Google Scholar 

  19. George SL. Identification and assessment of prognostic factors. Semin Oncol. 1988;15:462–71.

    PubMed  CAS  Google Scholar 

  20. Gospodarowicz MK, O’Sullivan B, Koh ES. Prognostic factors: principles and applications. In: Gospodarowicz MK, O’Sullivan B, Sobin LH, editors. Prognostic factors in cancer. 3rd ed. Hoboken, NJ: Wiley-Liss; 2006.

    Google Scholar 

  21. Byar DP. Identification of prognostic factors. In: Buyse ME, Staquet MJ, Sylvester RJ, editors. Cancer clinical trials. Methods and practice. Oxford: Oxford University Press; 1988.

    Google Scholar 

  22. Riley RD, Sauerbrei W, Altman DG. Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond. Br J Cancer. 2009;100:1219–29.

    Article  PubMed  CAS  Google Scholar 

  23. Byar DP. Problems with using observational databases to compare treatments. Stat Med. 1991;10:663–6.

    Article  PubMed  CAS  Google Scholar 

  24. Simon R. Importance of prognostic factors in cancer clinical trials. Cancer Treat Rep. 1984;68:185–92.

    PubMed  CAS  Google Scholar 

  25. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.

    Article  PubMed  Google Scholar 

  26. Altman DG. Studies investigating prognostic factors: conduct and evaluation. In: Gospodarowicz MK, O’Sullivan B, Sobin LH, editors. Prognostic factors in cancer. 3rd ed. Hoboken, NJ: Wiley-Liss; 2006.

    Google Scholar 

  27. Burke HB, Henson DE. The American Joint Committee on Cancer. Criteria for prognostic factors and for an enhanced prognostic system. Cancer. 1993;72:3131–5.

    Article  PubMed  CAS  Google Scholar 

  28. Cox DR. Regression models and life-tables. J R Stat Soc B. 1972;34:187–220.

    Google Scholar 

  29. Simon R. Evaluating prognostic factor studies. In: Gospodarowicz MK, Henson DE, Hutter RVP, et al., editors. Prognostic factors in cancer. 2nd ed. New York: Wiley-Liss; 2001.

    Google Scholar 

  30. Kaplan HS, Dorfman RF, Nelsen TS, et al. Staging laparotomy and splenectomy in Hodgkin’s disease: analysis of indications and patterns of involvement in 285 consecutive, unselected patients. Natl Cancer Inst Monogr. 1973;36:291–301.

    PubMed  CAS  Google Scholar 

  31. Piro AJ, Hellman S, Moloney WC. The influence of laparotomy on management decisions in Hodgkin’s disease. Arch Intern Med. 1972;130:844–8.

    Article  PubMed  CAS  Google Scholar 

  32. Hoppe RT, Coleman CN, Cox RS, et al. The management of stage I–II Hodgkin’s disease with irradiation alone or combined modality therapy: the Stanford experience. Blood. 1982;59:455–65.

    PubMed  CAS  Google Scholar 

  33. Horwich A, Easton D, Nogueira-Costa R, et al. An analysis of prognostic factors in early stage Hodgkin’s disease. Radiother Oncol. 1986;7:95–106.

    Article  PubMed  CAS  Google Scholar 

  34. Lee CK, Bloomfield CD, Goldman AI, et al. Prognostic significance of mediastinal involvement in Hodgkin’s disease treated with curative radiotherapy. Cancer. 1980;46:2403–9.

    Article  PubMed  CAS  Google Scholar 

  35. Mauch P, Tarbell N, Weinstein H, et al. Stage IA and IIA supradiaphragmatic Hodgkin’s disease: prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation. J Clin Oncol. 1988;6:1576–83.

    PubMed  CAS  Google Scholar 

  36. Mendenhall NP, Cantor AB, Barre DM, et al. The role of prognostic factors in treatment selection for early-stage Hodgkin’s disease. Am J Clin Oncol. 1994;17:189–95.

    Article  PubMed  CAS  Google Scholar 

  37. Tubiana M, Henry-Amar M, Hayat M, et al. Prognostic significance of the number of involved areas in the early stages of Hodgkin’s disease. Cancer. 1984;54:885–94.

    Article  PubMed  CAS  Google Scholar 

  38. Willett CG, Linggood RM, Leong JC, et al. Stage IA to IIB mediastinal Hodgkin’s disease: three-dimensional volumetric assessment of response to treatment. J Clin Oncol. 1988;6:819–24.

    PubMed  CAS  Google Scholar 

  39. Enblad G. Hodgkin’s disease in young and elderly patients. Clinical and pathological studies. Minireview based on a doctoral thesis. Ups J Med Sci. 1994;99:1–38.

    Article  PubMed  CAS  Google Scholar 

  40. Specht L. Tumor burden as the main indicator of prognosis in Hodgkin’s disease. Eur J Cancer. 1992;28A:1982–5.

    Article  PubMed  CAS  Google Scholar 

  41. Specht L, Nordentoft AM, Cold S, et al. Tumor burden as the most important prognostic factor in early stage Hodgkin’s disease. Relations to other prognostic factors and implications for choice of treatment. Cancer. 1988;61:1719–27.

    Article  PubMed  CAS  Google Scholar 

  42. Enrici RM, Osti MF, Anselmo AP, et al. Hodgkin’s disease stage I and II with exclusive subdiaphragmatic presentation. The experience of the Departments of Radiation Oncology and Hematology, University “La Sapienza” of Rome. Tumori. 1996;82:48–52.

    PubMed  CAS  Google Scholar 

  43. Hagemeister FB, Fuller LM, Velasquez WS, et al. Stage I and II Hodgkin’s disease: involved-field radiotherapy versus extended-field radiotherapy versus involved-field radiotherapy followed by six cycles of MOPP. Cancer Treat Rep. 1982;66:789–98.

    PubMed  CAS  Google Scholar 

  44. Hoppe RT, Horning SJ, Rosenberg SA. The concept, evolution and preliminary results of the current Stanford clinical trials for Hodgkin’s disease. Cancer Surv. 1985;4:459–75.

    PubMed  CAS  Google Scholar 

  45. Mauch P, Gorshein D, Cunningham J, et al. Influence of mediastinal adenopathy on site and frequency of relapse in patients with Hodgkin’s disease. Cancer Treat Rep. 1982;66:809–17.

    PubMed  CAS  Google Scholar 

  46. Prosnitz LR, Curtis AM, Knowlton AH, et al. Supradiaphragmatic Hodgkin’s disease: significance of large mediastinal masses. Int J Radiat Oncol Biol Phys. 1980;6:809–13.

    Article  PubMed  CAS  Google Scholar 

  47. Specht L. Prognostic factors in Hodgkin’s disease. Cancer Treat Rev. 1991;18:21–53.

    Article  PubMed  CAS  Google Scholar 

  48. Tarbell NJ, Thompson L, Mauch P. Thoracic irradiation in Hodgkin’s disease: disease control and long-term complications. Int J Radiat Oncol Biol Phys. 1990;18:275–81.

    Article  PubMed  CAS  Google Scholar 

  49. Connors JM, Klimo P. Is it an E lesion or stage IV? An unsettled issue in Hodgkin’s disease staging. J Clin Oncol. 1984;2:1421–3.

    PubMed  CAS  Google Scholar 

  50. Levi JA, Wiernik PH. Limited extranodal Hodgkin’s disease. Unfavorable prognosis and therapeutic implications. Am J Med. 1977;63:365–72.

    Article  PubMed  CAS  Google Scholar 

  51. Prosnitz LR. The Ann Arbor staging system for Hodgkin’s disease: does E stand for error? Int J Radiat Oncol Biol Phys. 1977;2:1039.

    Google Scholar 

  52. Franklin J, Paulus U, Lieberz D, et al. Is the international prognostic score for advanced stage Hodgkin’s disease applicable to early stage patients? German Hodgkin Lymphoma Study Group. Ann Oncol. 2000;11:617–23.

    Article  PubMed  CAS  Google Scholar 

  53. Gobbi PG, Gendarini A, Crema A, et al. Serum albumin in Hodgkin’s disease. Cancer. 1985;55:389–93.

    Article  PubMed  CAS  Google Scholar 

  54. Gospodarowicz MK, Sutcliffe SB, Clark RM, et al. Analysis of supradiaphragmatic clinical stage I and II Hodgkin’s disease treated with radiation alone. Int J Radiat Oncol Biol Phys. 1992;22:859–65.

    Article  PubMed  CAS  Google Scholar 

  55. Haybittle JL, Hayhoe FG, Easterling MJ, et al. Review of British National Lymphoma Investigation studies of Hodgkin’s disease and development of prognostic index. Lancet. 1985;1:967–72.

    Article  PubMed  CAS  Google Scholar 

  56. Tubiana M, Henry-Amar M, Werf-Messing B, et al. A multivariate analysis of prognostic factors in early stage Hodgkin’s disease. Int J Radiat Oncol Biol Phys. 1985;11:23–30.

    Article  PubMed  CAS  Google Scholar 

  57. Vaughan HB, MacLennan KA, Bennett MH, et al. Systemic disturbance in Hodgkin’s disease and its relation to histopathology and prognosis (BNLI report No. 30). Clin Radiol. 1987;38:257–61.

    Article  Google Scholar 

  58. Vaughan HB, MacLennan KA, Easterling MJ, et al. The prognostic significance of age in Hodgkin’s disease: examination of 1500 patients (BNLI report no. 23). Clin Radiol. 1983;34:503–6.

    Article  Google Scholar 

  59. Franklin J, Pluetschow A, Paus M, et al. Second malignancy risk associated with treatment of Hodgkin’s lymphoma: meta-analysis of the randomised trials. Ann Oncol. 2006;17:1749–60.

    Article  PubMed  CAS  Google Scholar 

  60. Specht L. Very long-term follow-up of the Danish National Hodgkin Study Group’s randomized trial of radiotherapy (RT) alone vs. combined modality treatment (CMT) for early stage Hodgkin lymphoma, with special reference to second tumors and overall survival. Blood. 2003;102:637A.

    Google Scholar 

  61. Specht L, Gray RG, Clarke MJ, et al. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin’s disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin’s Disease Collaborative Group. J Clin Oncol. 1998;16:830–43.

    PubMed  CAS  Google Scholar 

  62. Bonfante V, Santoro A, Viviani S, et al. Early stage Hodgkin’s disease: ten-year results of a non-randomised study with radiotherapy alone or combined with MOPP. Eur J Cancer. 1993;29A:24–9.

    Article  Google Scholar 

  63. Glimelius I, Molin D, Amini RM, et al. Bulky disease is the most important prognostic factor in Hodgkin lymphoma stage IIB. Eur J Haematol. 2003;71:327–33.

    Article  PubMed  Google Scholar 

  64. Pavlovsky S, Maschio M, Santarelli MT, et al. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin’s disease. J Natl Cancer Inst. 1988;80:1466–73.

    Article  PubMed  CAS  Google Scholar 

  65. Tubiana M, Henry-Amar M, Carde P, et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin’s disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987. Blood. 1989;73:47–56.

    PubMed  CAS  Google Scholar 

  66. Gobbi PG, Broglia C, Di Giulio G, et al. The clinical value of tumor burden at diagnosis in Hodgkin lymphoma. Cancer. 2004;101:1824–34.

    Article  PubMed  Google Scholar 

  67. Gobbi PG, Ghirardelli ML, Solcia M, et al. Image-aided estimate of tumor burden in Hodgkin’s disease: evidence of its primary prognostic importance. J Clin Oncol. 2001;19:1388–94.

    PubMed  CAS  Google Scholar 

  68. Grow A, Quon A, Graves EE, et al. Metabolic tumor volume as an independent prognostic factor in lymphoma. J Clin Oncol. 2005;23 Suppl:583S.

    Google Scholar 

  69. Hutchings M, Berthelsen AK, Jakobsen AL, et al. Volume of abnormal tumor tissue on FDG-PET – a predictor of progression-free survival in Hodgkin lymphoma? Int J Radiat Oncol Biol Phys. 2005;63:S45.

    Google Scholar 

  70. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107:52–9.

    Article  PubMed  CAS  Google Scholar 

  71. Hutchings M, Mikhaeel NG, Fields PA, et al. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol. 2005;16:1160–8.

    Article  PubMed  CAS  Google Scholar 

  72. Kostakoglu L, Coleman M, Leonard JP, et al. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease. J Nucl Med. 2002;43:1018–27.

    PubMed  Google Scholar 

  73. Sher DJ, Mauch PM, Van Den AA, et al. Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin’s lymphoma: the importance of involved-field radiotherapy. Ann Oncol. 2009;20(11):1848–53.

    Article  PubMed  CAS  Google Scholar 

  74. Herbst C, Rehan FA, Brillant C, et al. Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin lymphoma: a systematic review. Haematologica. 2010;95:494–500

    Google Scholar 

  75. Loeffler M, Brosteanu O, Hasenclever D, et al. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin’s disease. International Database on Hodgkin’s Disease Overview Study Group. J Clin Oncol. 1998;16:818–29.

    PubMed  CAS  Google Scholar 

  76. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med. 1998;339:1506–14.

    Article  PubMed  CAS  Google Scholar 

  77. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327:1478–84.

    Article  PubMed  CAS  Google Scholar 

  78. Ferme C, Bastion Y, Brice P, et al. Prognosis of patients with advanced Hodgkin’s disease: evaluation of four prognostic models using 344 patients included in the Group d’Etudes des Lymphomes de l’Adulte Study. Cancer. 1997;80:1124–33.

    Article  PubMed  CAS  Google Scholar 

  79. Low SE, Horsman JM, Walters SJ, et al. Risk-adjusted prognostic models for Hodgkin’s disease (HD) and grade II non-Hodgkin’s lymphoma (NHL II): validation on 6728 British National Lymphoma Investigation patients. Br J Haematol. 2003;120:277–80.

    Article  PubMed  Google Scholar 

  80. Peterson BA, Pajak TF, Cooper MR, et al. Effect of age on therapeutic response and survival in advanced Hodgkin’s disease. Cancer Treat Rep. 1982;66:889–98.

    PubMed  CAS  Google Scholar 

  81. Proctor SJ, Taylor P, Donnan P, et al. A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin’s disease at diagnosis. Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party. Eur J Cancer. 1991;27:624–9.

    Article  PubMed  CAS  Google Scholar 

  82. Specht L, Nissen NI. Prognostic factors in Hodgkin’s disease stage III with special reference to tumor burden. Eur J Haematol. 1988;41:80–7.

    Article  PubMed  CAS  Google Scholar 

  83. Specht L, Nissen NI. Prognostic factors in Hodgkin’s disease stage IV. Eur J Haematol. 1988;41:359–67.

    Article  PubMed  CAS  Google Scholar 

  84. Straus DJ, Gaynor JJ, Myers J, et al. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin’s disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol. 1990;8:1173–86.

    PubMed  CAS  Google Scholar 

  85. Proctor SJ, Rueffer JU, Angus B, et al. Hodgkin’s disease in the elderly: current status and future directions. Ann Oncol. 2002;13 Suppl 1:133–7.

    Article  PubMed  Google Scholar 

  86. Engert A, Ballova V, Haverkamp H, et al. Hodgkin’s lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin’s Study Group. J Clin Oncol. 2005;23:5052–60.

    Article  PubMed  Google Scholar 

  87. van Spronsen DJ, Janssen-Heijnen ML, Lemmens VE, et al. Independent prognostic effect of co-morbidity in lymphoma patients: results of the population-based Eindhoven Cancer Registry. Eur J Cancer. 2005;41:1051–7.

    Article  PubMed  Google Scholar 

  88. Gobbi PG, Comelli M, Grignani GE, et al. Estimate of expected survival at diagnosis in Hodgkin’s disease: a means of weighting prognostic factors and a tool for treatment choice and clinical research. A report from the International Database on Hodgkin’s Disease (IDHD). Haematologica. 1994;79:241–55.

    PubMed  CAS  Google Scholar 

  89. Klimm B, Reineke T, Haverkamp H, et al. Role of hematotoxicity and sex in patients with Hodgkin’s lymphoma: an analysis from the German Hodgkin Study Group. J Clin Oncol. 2005;23:8003–11.

    Article  PubMed  CAS  Google Scholar 

  90. Ranson MR, Radford JA, Swindell R, et al. An analysis of prognostic factors in stage III and IV Hodgkin’s disease treated at a single centre with MVPP. Ann Oncol. 1991;2:423–9.

    PubMed  CAS  Google Scholar 

  91. Somers R, Carde P, Henry-Amar M, et al. A randomized study in stage IIIB and IV Hodgkin’s disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial. J Clin Oncol. 1994;12:279–87.

    PubMed  CAS  Google Scholar 

  92. Georgii A, Fischer R, Hubner K, et al. Classification of Hodgkin’s disease biopsies by a panel of four histopathologists. Report of 1,140 patients from the German National Trial. Leuk Lymphoma. 1993;9:365–70.

    Article  PubMed  CAS  Google Scholar 

  93. Hess JL, Bodis S, Pinkus G, et al. Histopathologic grading of nodular sclerosis Hodgkin’s disease. Lack of prognostic significance in 254 surgically staged patients. Cancer. 1994;74:708–14.

    Article  PubMed  CAS  Google Scholar 

  94. MacLennan KA, Bennett MH, Tu A, et al. Relationship of histopathologic features to survival and relapse in nodular sclerosing Hodgkin’s disease. A study of 1659 patients. Cancer. 1989;64:1686–93.

    Article  PubMed  CAS  Google Scholar 

  95. Masih AS, Weisenburger DD, Vose JM, et al. Histologic grade does not predict prognosis in optimally treated, advanced-stage nodular sclerosing Hodgkin’s disease. Cancer. 1992;69:228–32.

    Article  PubMed  CAS  Google Scholar 

  96. van Spronsen DJ, Vrints LW, Hofstra G, et al. Disappearance of prognostic significance of histopathological grading of nodular sclerosing Hodgkin’s disease for unselected patients, 1972-92. Br J Haematol. 1997;96:322–7.

    Article  PubMed  Google Scholar 

  97. Torricelli P, Grimaldi PL, Fiocchi F, et al. Hodgkin’s disease: a quantitative evaluation by computed tomography of tumor burden. Clin Imaging. 2004;28:239–44.

    Article  PubMed  Google Scholar 

  98. Hoppe RT, Cox RS, Rosenberg SA, et al. Prognostic factors in pathologic stage III Hodgkin’s disease. Cancer Treat Rep. 1982;66:743–9.

    PubMed  CAS  Google Scholar 

  99. Mauch P, Goffman T, Rosenthal DS, et al. Stage III Hodgkin’s disease: improved survival with combined modality therapy as compared with radiation therapy alone. J Clin Oncol. 1985;3:1166–73.

    PubMed  CAS  Google Scholar 

  100. Powlis WD, Mauch P, Goffman T, et al. Treatment of patients with “minimal” stage IIIA Hodgkin’s disease. Int J Radiat Oncol Biol Phys. 1987;13:1437–42.

    Article  PubMed  CAS  Google Scholar 

  101. Stein RS, Golomb HM, Wiernik PH, et al. Anatomic substages of stage IIIA Hodgkin’s disease: followup of a collaborative study. Cancer Treat Rep. 1982;66:733–41.

    PubMed  CAS  Google Scholar 

  102. Brada M, Ashley S, Nicholls J, et al. Stage III Hodgkin’s disease–long-term results following chemotherapy, radiotherapy and combined modality therapy. Radiother Oncol. 1989;14:185–98.

    Article  PubMed  CAS  Google Scholar 

  103. Desser RK, Golomb HM, Ultmann JE, et al. Prognostic classification of Hodgkin disease in pathologic stage III, based on anatomic considerations. Blood. 1977;49:883–93.

    PubMed  CAS  Google Scholar 

  104. Golomb HM, Sweet DL, Ultmann JE, et al. Importance of substaging of stage III Hodgkin’s disease. Semin Oncol. 1980;7:136–43.

    PubMed  CAS  Google Scholar 

  105. Proctor SJ, Taylor P, Mackie MJ, et al. A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin’s disease at diagnosis. The Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party. Leuk Lymphoma. 1992;7 Suppl:17–20.

    Google Scholar 

  106. Hasenclever D, Schmitz N, Diehl V. Is there a rationale for high-dose chemotherapy as first line treatment of advanced Hodgkin’s disease? German Hodgkin’s Lymphoma Study Group (GHSG). Leuk Lymphoma. 1995;15 Suppl 1:47–9.

    Article  PubMed  Google Scholar 

  107. Gobbi PG, Cavalli C, Gendarini A, et al. Prognostic significance of serum albumin in Hodgkin’s disease. Haematologica. 1986;71:95–102.

    PubMed  CAS  Google Scholar 

  108. Straus DJ. High-risk Hodgkin’s disease prognostic factors. Leuk Lymphoma. 1995;15 Suppl 1:41–2.

    Article  PubMed  Google Scholar 

  109. Loeffler M, Pfreundschuh M, Hasenclever D, et al. Prognostic risk factors in advanced Hodgkin’s lymphoma. Report of the German Hodgkin Study Group. Blut. 1988;56:273–81.

    Article  PubMed  CAS  Google Scholar 

  110. Aviles A, Talavera A, Garcia EL, et al. La fosfatasa alcalina como factor pronóstico en enfermedad de Hodgkin (Alkaline phosphatase as a prognostic factor in Hodgkin’s disease). Rev Gastroenterol Mex. 1990;55:211–4.

    PubMed  CAS  Google Scholar 

  111. Wagstaff J, Gregory WM, Swindell R, et al. Prognostic factors for survival in stage IIIB and IV Hodgkin’s disease: a multivariate analysis comparing two specialist treatment centres. Br J Cancer. 1988;58:487–92.

    Article  PubMed  CAS  Google Scholar 

  112. MacLennan KA, Vaughan HB, Easterling MJ, et al. The presentation haemoglobin level in 1103 patients with Hodgkin’s disease (BNLI report no. 21). Clin Radiol. 1983;34:491–5.

    Article  PubMed  CAS  Google Scholar 

  113. Brusamolino E, Orlandi E, Morra E, et al. Analysis of long-term results and prognostic factors among 138 patients with advanced Hodgkin’s disease treated with the alternating MOPP/ABVD chemotherapy. Ann Oncol. 1994;5 Suppl 2:53–7.

    Article  PubMed  Google Scholar 

  114. Carde P, MacKintosh FR, Rosenberg SA. A dose and time response analysis of the treatment of Hodgkin’s disease with MOPP chemotherapy. J Clin Oncol. 1983;1:146–53.

    PubMed  CAS  Google Scholar 

  115. DeVita Jr VT, Simon RM, Hubbard SM, et al. Curability of advanced Hodgkin’s disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med. 1980;92:587–95.

    PubMed  Google Scholar 

  116. Munker R, Hasenclever D, Brosteanu O, et al. Bone marrow involvement in Hodgkin’s disease: an analysis of 135 consecutive cases. German Hodgkin’s Lymphoma Study Group. J Clin Oncol. 1995;13:403–9.

    PubMed  CAS  Google Scholar 

  117. Bonadonna G, Valagussa P, Santoro A. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin’s disease. A report of 8-year results. Ann Intern Med. 1986;104:739–46.

    PubMed  CAS  Google Scholar 

  118. Longo DL, Young RC, Wesley M, et al. Twenty years of MOPP therapy for Hodgkin’s disease. J Clin Oncol. 1986;4:1295–306.

    PubMed  CAS  Google Scholar 

  119. Selby P, Patel P, Milan S, et al. ChlVPP combination chemotherapy for Hodgkin’s disease: long-term results. Br J Cancer. 1990;62:279–85.

    Article  PubMed  CAS  Google Scholar 

  120. Jaffe HS, Cadman EC, Farber LR, et al. Pretreatment hematocrit as an independent prognostic variable in Hodgkin’s disease. Blood. 1986;68:562–4.

    PubMed  CAS  Google Scholar 

  121. Pillai GN, Hagemeister FB, Velasquez WS, et al. Prognostic factors for Stage IV Hodgkin’s disease treated with MOPP, with or without bleomycin. Cancer. 1985;55:691–7.

    Article  PubMed  CAS  Google Scholar 

  122. Dimopoulos MA, Cabanillas F, Lee JJ, et al. Prognostic role of serum beta 2-microglobulin in Hodgkin’s disease. J Clin Oncol. 1993;11:1108–11.

    PubMed  CAS  Google Scholar 

  123. Vassilakopoulos TP, Nadali G, Angelopoulou MK, et al. The prognostic significance of beta(2)-microglobulin in patients with Hodgkin’s lymphoma. Haematologica. 2002;87:701–8.

    PubMed  CAS  Google Scholar 

  124. Gause A, Jung W, Keymis S, et al. The clinical significance of cytokines and soluble forms of membrane-derived activation antigens in the serum of patients with Hodgkin’s disease. Leuk Lymphoma. 1992;7:439–47.

    Article  PubMed  CAS  Google Scholar 

  125. Gause A, Jung W, Schmits R, et al. Soluble CD8, CD25 and CD30 antigens as prognostic markers in patients with untreated Hodgkin’s lymphoma. Ann Oncol. 1992;3 Suppl 4:49–52.

    Article  PubMed  Google Scholar 

  126. Nadali G, Vinante F, Ambrosetti A, et al. Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin’s disease and correlate with clinical features and prognosis. J Clin Oncol. 1994;12:793–7.

    PubMed  CAS  Google Scholar 

  127. Pizzolo G, Vinante F, Chilosi M, et al. Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin’s disease: relationship with disease activity and clinical stage. Br J Haematol. 1990;75:282–4.

    Article  PubMed  CAS  Google Scholar 

  128. Axdorph U, Sjoberg J, Grimfors G, et al. Biological markers may add to prediction of outcome achieved by the International Prognostic Score in Hodgkin’s disease. Ann Oncol. 2000;11:1405–11.

    Article  PubMed  CAS  Google Scholar 

  129. Casasnovas RO, Mounier N, Brice P, et al. Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin’s lymphoma: a study from the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2007;25:1732–40.

    Article  PubMed  CAS  Google Scholar 

  130. Zanotti R, Trolese A, Ambrosetti A, et al. Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin’s lymphoma. Ann Oncol. 2002;13:1908–14.

    Article  PubMed  CAS  Google Scholar 

  131. Gallamini A, Rigacci L, Merli F, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin’s disease. Haematologica. 2006;91:475–81.

    PubMed  Google Scholar 

  132. Zinzani PL, Tani M, Fanti S, et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin’s disease patients. Ann Oncol. 2006;17:1296–300.

    Article  PubMed  CAS  Google Scholar 

  133. Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25:3746–52.

    Article  PubMed  CAS  Google Scholar 

  134. Avigdor A, Bulvik S, Levi I, et al. Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin’s lymphoma. Ann Oncol. 2009;21(1):126–32.

    Article  PubMed  Google Scholar 

  135. Wagstaff J, Steward W, Jones M, et al. Factors affecting remission and survival in patients with advanced Hodgkin’s disease treated with MVPP. Hematol Oncol. 1986;4:135–47.

    Article  PubMed  CAS  Google Scholar 

  136. Gobbi PG, Gobbi PG, Mazza P, et al. Multivariate analysis of Hodgkin’s disease prognosis. Fitness and use of a directly predictive equation. Haematologica. 1989;74:29–38.

    PubMed  CAS  Google Scholar 

  137. Low SE, Horsman JM, Hancock H, et al. Prognostic markers in malignant lymphoma: an analysis of 1,198 patients treated at a single centre. Int J Oncol. 2001;19:1203–9.

    PubMed  CAS  Google Scholar 

  138. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med. 2003;348:2386–95.

    Article  PubMed  CAS  Google Scholar 

  139. Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial. J Clin Oncol. 2003;21:607–14.

    Article  PubMed  CAS  Google Scholar 

  140. Gobbi PG, Zinzani PL, Broglia C, et al. Comparison of prognostic models in patients with advanced Hodgkin disease. Promising results from integration of the best three systems. Cancer. 2001;91:1467–78.

    Article  PubMed  CAS  Google Scholar 

  141. Johnson PW, Radford JA, Cullen MH, et al. Comparison of ABVD and Alternating or Hybrid Multidrug Regimens for the Treatment of Advanced Hodgkin’s Lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol. 2005;23:9208–18.

    Article  PubMed  CAS  Google Scholar 

  142. Radford JA, Rohatiner AZ, Ryder WD, et al. ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin’s disease. J Clin Oncol. 2002;20:2988–94.

    Article  PubMed  CAS  Google Scholar 

  143. Bierman PJ, Lynch JC, Bociek RG, et al. The International Prognostic Factors Project score for advanced Hodgkin’s disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation. Ann Oncol. 2002;13:1370–7.

    Article  PubMed  CAS  Google Scholar 

  144. Gisselbrecht C, Mounier N, Andre M, et al. How to define intermediate stage in Hodgkin’s lymphoma? Eur J Haematol Suppl. 2005;(66):111–14.

    Google Scholar 

  145. Healey EA, Tarbell NJ, Kalish LA, et al. Prognostic factors for patients with Hodgkin disease in first relapse. Cancer. 1993;71:2613–20.

    Article  PubMed  CAS  Google Scholar 

  146. Mauch PM. Controversies in the management of early stage Hodgkin’s disease. Blood. 1994;83:318–29.

    PubMed  CAS  Google Scholar 

  147. Bonfante V, Santoro A, Viviani S, et al. Outcome of patients with Hodgkin’s disease failing after primary MOPP-ABVD. J Clin Oncol. 1997;15:528–34.

    PubMed  CAS  Google Scholar 

  148. Brice P, Bastion Y, Divine M, et al. Analysis of prognostic factors after the first relapse of Hodgkin’s disease in 187 patients. Cancer. 1996;78:1293–9.

    Article  PubMed  CAS  Google Scholar 

  149. Canellos GP, Petroni GR, Barcos M, et al. Etoposide, vinblastine, and doxorubicin: an active regimen for the treatment of Hodgkin’s disease in relapse following MOPP. Cancer and Leukemia Group B. J Clin Oncol. 1995;13:2005–11.

    PubMed  CAS  Google Scholar 

  150. Ferme C, Bastion Y, Lepage E, et al. The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin’s disease. Ann Oncol. 1995;6:543–9.

    PubMed  CAS  Google Scholar 

  151. Lohri A, Barnett M, Fairey RN, et al. Outcome of treatment of first relapse of Hodgkin’s disease after primary chemotherapy: identification of risk factors from the British Columbia experience 1970 to 1988. Blood. 1991;77:2292–8.

    PubMed  CAS  Google Scholar 

  152. Longo DL, Duffey PL, Young RC, et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin’s disease after combination chemotherapy: the low probability for cure. J Clin Oncol. 1992;10:210–8.

    PubMed  CAS  Google Scholar 

  153. Straus DJ, Myers J, Koziner B, et al. Combination chemotherapy for the treatment of Hodgkin’s disease in relapse. Results with lomustine (CCNU), melphalan (Alkeran), and vindesine (DVA) alone (CAD) and in alternation with MOPP and doxorubicin (Adriamycin), bleomycin, and vinblastine (ABV). Cancer Chemother Pharmacol. 1983;11:80–5.

    Article  PubMed  CAS  Google Scholar 

  154. Viviani S, Santoro A, Negretti E, et al. Salvage chemotherapy in Hodgkin’s disease. Results in patients relapsing more than twelve months after first complete remission. Ann Oncol. 1990;1:123–7.

    PubMed  CAS  Google Scholar 

  155. Josting A, Franklin J, May M, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin’s lymphoma registered in the database of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol. 2001;20:221–30.

    Article  Google Scholar 

  156. Josting A, Schmitz N. Insights into 25 years of clinical trials of the GHSG: relapsed and refractory Hodgkin’s disease. In: Diehl V, Josting A, editors. 25 years German Hodgkin Study Group. Munich: Urban & Vogel; 2004.

    Google Scholar 

  157. Hagemeister FB, Tannir N, McLaughlin P, et al. MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin’s disease. J Clin Oncol. 1987;5:556–61.

    PubMed  CAS  Google Scholar 

  158. Perren TJ, Selby PJ, Milan S, et al. Etoposide and adriamycin containing combination chemotherapy (HOPE-Bleo) for relapsed Hodgkin’s disease. Br J Cancer. 1990;61:919–23.

    Article  PubMed  CAS  Google Scholar 

  159. Salvagno L, Soraru M, Aversa SM, et al. Late relapses in Hodgkin’s disease: outcome of patients relapsing more than twelve months after primary chemotherapy. Ann Oncol. 1993;4:657–62.

    PubMed  CAS  Google Scholar 

  160. Brada M, Eeles R, Ashley S, et al. Salvage radiotherapy in recurrent Hodgkin’s disease. Ann Oncol. 1992;3:131–5.

    PubMed  CAS  Google Scholar 

  161. Josting A, Nogova L, Franklin J, et al. Salvage radiotherapy in patients with relapsed and refractory Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol. 2005;23:1522–9.

    Article  PubMed  Google Scholar 

  162. Leigh BR, Fox KA, Mack CF, et al. Radiation therapy salvage of Hodgkin’s disease following chemotherapy failure. Int J Radiat Oncol Biol Phys. 1993;27:855–62.

    Article  PubMed  CAS  Google Scholar 

  163. Mauch P, Tarbell N, Skarin A, et al. Wide-field radiation therapy alone or with chemotherapy for Hodgkin’s disease in relapse from combination chemotherapy. J Clin Oncol. 1987;5:544–9.

    PubMed  CAS  Google Scholar 

  164. O’Brien PC, Parnis FX. Salvage radiotherapy following chemotherapy failure in Hodgkin’s disease – what is its role? Acta Oncol. 1995;34:99–104.

    Article  PubMed  Google Scholar 

  165. Roach III M, Kapp DS, Rosenberg SA, et al. Radiotherapy with curative intent: an option in selected patients relapsing after chemotherapy for advanced Hodgkin’s disease. J Clin Oncol. 1987;5:550–5.

    PubMed  Google Scholar 

  166. Wirth A, Corry J, Laidlaw C, et al. Salvage radiotherapy for Hodgkin’s disease following chemotherapy failure. Int J Radiat Oncol Biol Phys. 1997;39:599–607.

    Article  PubMed  CAS  Google Scholar 

  167. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet. 1993;341:1051–4.

    Article  PubMed  CAS  Google Scholar 

  168. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359:2065–71.

    Article  PubMed  CAS  Google Scholar 

  169. Anderson JE, Litzow MR, Appelbaum FR, et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin’s disease: the 21-year Seattle experience. J Clin Oncol. 1993;11:2342–50.

    PubMed  CAS  Google Scholar 

  170. Argiris A, Seropian S, Cooper DL. High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin’s disease. Ann Oncol. 2000;11:665–72.

    Article  PubMed  CAS  Google Scholar 

  171. Bierman PJ, Anderson JR, Freeman MB, et al. High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin’s disease patients following first relapse after chemotherapy. Ann Oncol. 1996;7:151–6.

    Article  PubMed  CAS  Google Scholar 

  172. Ferme C, Mounier N, Divine M, et al. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin’s disease in relapse or failure after initial chemotherapy: results of the Groupe d’Etudes des Lymphomes de l’Adulte H89 Trial. J Clin Oncol. 2002;20:467–75.

    Article  PubMed  CAS  Google Scholar 

  173. Hahn T, Benekli M, Wong C, et al. A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin’s disease. Bone Marrow Transplant. 2005;35:557–66.

    Article  PubMed  CAS  Google Scholar 

  174. Josting A, Rudolph C, Mapara M, et al. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol. 2005;16:116–23.

    Article  PubMed  CAS  Google Scholar 

  175. Lazarus HM, Loberiza Jr FR, Zhang MJ, et al. Autotransplants for Hodgkin’s disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR). Bone Marrow Transplant. 2001;27:387–96.

    Article  PubMed  CAS  Google Scholar 

  176. Poen JC, Hoppe RT, Horning SJ. High-dose therapy and autologous bone marrow transplantation for relapsed/refractory Hodgkin’s disease: the impact of involved field radiotherapy on patterns of failure and survival. Int J Radiat Oncol Biol Phys. 1996;36:3–12.

    Article  PubMed  CAS  Google Scholar 

  177. Sureda A, Constans M, Iriondo A, et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin’s lymphoma autografted after a first relapse. Ann Oncol. 2005;16:625–33.

    Article  PubMed  CAS  Google Scholar 

  178. Yahalom J, Gulati SC, Toia M, et al. Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin’s disease. J Clin Oncol. 1993;11:1062–70.

    PubMed  CAS  Google Scholar 

  179. Popat U, Hosing C, Saliba RM, et al. Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin’s lymphoma. Bone Marrow Transplant. 2004;33:1015–23.

    Article  PubMed  CAS  Google Scholar 

  180. Stewart DA, Guo D, Gluck S, et al. Double high-dose therapy for Hodgkin’s disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation. Bone Marrow Transplant. 2000;26:383–8.

    Article  PubMed  CAS  Google Scholar 

  181. Lumley MA, Milligan DW, Knechtli CJ, et al. High lactate dehydrogenase level is associated with an adverse outlook in autografting for Hodgkin’s disease. Bone Marrow Transplant. 1996;17:383–8.

    PubMed  CAS  Google Scholar 

  182. Bierman PJ, Bagin RG, Jagannath S, et al. High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin’s disease: long-term follow-up in 128 patients. Ann Oncol. 1993;4:767–73.

    PubMed  CAS  Google Scholar 

  183. Brice P, Bouabdallah R, Moreau P, et al. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin’s disease: analysis of 280 patients from the French registry. Societe Francaise de Greffe de Moelle. Bone Marrow Transplant. 1997;20:21–6.

    Article  PubMed  CAS  Google Scholar 

  184. Chopra R, McMillan AK, Linch DC, et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin’s disease. A single-center eight-year study of 155 patients. Blood. 1993;81:1137–45.

    PubMed  CAS  Google Scholar 

  185. Horning SJ, Chao NJ, Negrin RS, et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin’s disease: analysis of the Stanford University results and prognostic indices. Blood. 1997;89:801–13.

    PubMed  CAS  Google Scholar 

  186. Wheeler C, Eickhoff C, Elias A, et al. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin’s disease: a prognostic model for treatment outcomes. Biol Blood Marrow Transplant. 1997;3:98–106.

    PubMed  CAS  Google Scholar 

  187. Williams CD, Goldstone AH, Pearce R, et al. Autologous bone marrow transplantation for pediatric Hodgkin’s disease: a case-matched comparison with adult patients by the European Bone Marrow Transplant Group Lymphoma Registry. J Clin Oncol. 1993;11:2243–9.

    PubMed  CAS  Google Scholar 

  188. Becherer A, Mitterbauer M, Jaeger U, et al. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. Leukemia. 2002;16:260–7.

    Article  PubMed  CAS  Google Scholar 

  189. Filmont JE, Gisselbrecht C, Cuenca X, et al. The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation. Cancer. 2007;110:1361–9.

    Article  PubMed  Google Scholar 

  190. Jabbour E, Hosing C, Ayers G, et al. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer. 2007;109:2481–9.

    Article  PubMed  Google Scholar 

  191. Schot BW, Pruim J, van Imhoff GW, et al. The role of serial pre-transplantation positron emission tomography in predicting progressive disease in relapsed lymphoma. Haematologica. 2006;91:490–5.

    PubMed  Google Scholar 

  192. Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood. 2003;102:53–9.

    Article  PubMed  CAS  Google Scholar 

  193. Svoboda J, Andreadis C, Elstrom R, et al. Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant. 2006;38:211–6.

    Article  PubMed  CAS  Google Scholar 

  194. Hasenclever D. The disappearance of prognostic factors in Hodgkin’s disease. Ann Oncol. 2002;13 Suppl 1:75–8.

    Article  PubMed  Google Scholar 

  195. Cosset JM, Mauch PM. The role of radiotherapy for early stage Hodgkin’s disease: limitations and perspectives. Ann Oncol. 1998;9 Suppl 5:S57–62.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Section 5073, The Finsen Centre, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, 2100, Copenhagen, Denmark

    Lena Specht

  2. Institut für Medizinische Informatik, Statistik & Epidemiologie (IMISE), Universität Leipzig, Härtelstrasse 16-18, 04107, Leipzig, Germany

    Dirk Hasenclever

Authors
  1. Lena Specht
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dirk Hasenclever
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lena Specht .

Editor information

Editors and Affiliations

  1. Klinik I für Innere Medizin, Universität Köln, Joseph-Stelzmann-Str. 9, Köln, 50924, Germany

    Andreas Engert

  2. Dept. Medicine, Stanford University, Stanford, 94305-5479, California, USA

    Sandra J. Horning

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Specht, L., Hasenclever, D. (2011). Prognostic Factors. In: Engert, A., Horning, S. (eds) Hodgkin Lymphoma. Hematologic Malignancies. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-12780-9_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-12780-9_7

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-12779-3

  • Online ISBN: 978-3-642-12780-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation